Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Dendrimer-nanoparticle (DEP) delivery of cabazitaxel (DEP-cabazitaxel): A first-in-human phase 1/2 trial in patients with advanced solid tumours

European Journal of Cancer(2026)10.1016/j.ejca.2026.116821Source: DataRank Database

Dendrimer-nanoparticle (DEP) delivery of cabazitaxel (DEP-cabazitaxel): A first-in-human phase 1/2 trial in patients with advanced solid tumours is a research paper published in European Journal of Cancer (2026). On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

0 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (8 grants)Impact (FWCI 0.00)OA: greenTopics (40)IDs (PubMed, OpenAlex)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (15)

David J. Pinato ORCID,Martin D. Forster,Anthony M. Joshua ORCID,James Korolewicz ORCID,Karam Aboud ORCID

Live enrichment

PubMed:42208277 OpenAlex:https://openalex.org/W7162110116

National Institute on Handicapped Research

Cancer Research UK

National Institute for Health and Care Research

NIHR Imperial Biomedical Research Centre

National Institute for Health Research (NIHR)

UCLH Biomedical Research Centre

Imperial Experimental Cancer Medicine Centre

Université Catholique de Louvain

FWCI

0.00

Citation Percentile

0.5%

greenLicense: cc-by-nc-nd

repositoryhttps://kclpure.kcl.ac.uk/portal/en/publications/ea69d1a4-7434-4d22-9c41-0392f6f013df

publisherhttps://api.elsevier.com/content/article/PII:S0959804926006027?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0959804926006027?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.ejca.2026.116821

Fields of Study

Dendrimers and Hyperbranched PolymersNanoparticle-Based Drug DeliveryCancer Research and TreatmentAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedAntineoplastic AgentsDendrimersMaximum Tolerated DoseNanoparticlesNeoplasmsProgression-Free SurvivalTaxoids

MeSH Terms

Progression-Free SurvivalAdultAgedAged, 80 and overAntineoplastic AgentsFemaleHumansMaleMiddle AgedNeoplasmsMaximum Tolerated DoseTaxoidsDendrimersNanoparticles

Keywords

CabazitaxelMaximum tolerated dosePhase (matter)Phases of clinical researchClinical trialOvarian cancerprostate cancerDendrimer NanoparticleEsophago-gastric Cancer

Dendrimer-nanoparticle (DEP) delivery of cabazitaxel (DEP-cabazitaxel): A first-in-human phase 1/2 trial in patients with advanced solid tumours

FAIR Checklist

Authors (15)

Funding (8 grants)

Impact

Open Access

Topics